BioLineRx (BLRX) Capital Expenditures (2013 - 2026)
BioLineRx (BLRX) posted quarterly Capital Expenditures of $6000.0 for Q4 2024, up 137.5% year-over-year from $2526.3 in Q1 2024, and up 122.22% quarter-over-quarter from -$27000.0 in Q2 2024.
Powered by 
Analysis
BioLineRx (BLRX) Capital Expenditures (2013 - 2026) Analysis & Trends
BioLineRx's Capital Expenditures history runs 12 years deep, the most recent figure standing at $6000.0 for Q4 2024.
- In Q4 2024, Capital Expenditures rose 137.5% year-over-year to $6000.0; the TTM figure through Dec 2024 stood at -$53000.0 (up 54.31% YoY), while the FY2025 annual figure was -$25000.0, up 52.83% from the prior year.
- Capital Expenditures for Q4 2024 stood at $6000.0, up from -$27000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $6000.0 in Q4 2024, with the low at -$67000.0 in Q2 2023.
- The 5-year median for Capital Expenditures is -$19000.0 (2021), against an average of -$24750.0.
- The sharpest annual moves came in 2021 and 2024: Capital Expenditures tumbled 6300.0% in 2021, then soared 137.5% in 2024.
- BioLineRx's Capital Expenditures stood at $1000.0 in 2020, then sank by 6300.0% to -$62000.0 in 2021, then gained by 8.06% to -$57000.0 in 2022, then soared by 71.93% to -$16000.0 in 2023, then jumped by 137.5% to $6000.0 in 2024.
- Business Quant data shows BLRX's Capital Expenditures at $6000.0 in Q4 2024, -$27000.0 in Q2 2024, and -$32000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 6.26 Mn |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -44,000.00 |
| Mar 31, 2022 | -18,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | -19,000.00 |
| Mar 31, 2021 | -19,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2019 | -13,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Jun 30, 2019 | -22,000.00 |